[1]

Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, et al. 2016. The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research 51:156−186

doi: 10.1016/j.preteyeres.2015.08.001
[2]

Lewis H, Abrams GW, Blumenkranz MS, Campo RV. 1992. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 99:753−759

doi: 10.1016/S0161-6420(92)31901-3
[3]

Yamamoto T, Hitani K, Tsukahara I, Yamamoto S, Kawasaki R, et al. 2003. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. American Journal of Ophthalmology 135:14−19

doi: 10.1016/S0002-9394(02)01819-6
[4]

Gandorfer A, Messmer EM, Ulbig MW, Kampik A. 2000. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 20:126−133

doi: 10.1097/00006982-200002000-00004
[5]

Dillinger P, Mester U. 2004. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefe’s Archive for Clinical and Experimental Ophthalmology 242:630−637

doi: 10.1007/s00417-003-0849-8
[6]

Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG. 2008. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina 28:410−419

doi: 10.1097/IAE.0b013e31816102f2
[7]

Recchia FM, Ruby AJ, Carvalho Recchia CA. 2005. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. American Journal of Ophthalmology 139:447−454

doi: 10.1016/j.ajo.2004.09.076
[8]

Yanyali A, Horozoglu F, Celik E, Nohutcu AF. 2007. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina 27:557−566

doi: 10.1097/01.iae.0000249390.61854.d5
[9]

Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, Beck RR, et al. 2010. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117:1087−1093.e3

doi: 10.1016/j.ophtha.2009.10.040
[10]

Jun SY, Hwang DD. 2022. Effect of vitrectomy with silicone oil tamponade and internal limiting membrane peeling on eyes with proliferative diabetic retinopathy. Scientific Reports 12:8076

doi: 10.1038/s41598-022-12113-8
[11]

Navajas EV, Schuck N, Govetto A, Akil H, Docherty G, et al. 2020. En face optical coherence tomography and optical coherence tomography angiography of inner retinal dimples after internal limiting membrane peeling for full-thickness macular holes. Retina 40:557−566

doi: 10.1097/IAE.0000000000002432
[12]

Han GH, Han DJ, Lee JH, Byeon SH, Shin JY. 2020. Tomographic structural changes of the inner retina after internal limiting membrane peeling for idiopathic epiretinal membrane. Korean Journal of Ophthalmology 34:235−241

doi: 10.3341/kjo.2019.0126
[13]

Bhagat N, Grigorian RA, Tutela A, Zarbin MA. 2009. Diabetic macular edema: pathogenesis and treatment. Survey of Ophthalmology 54:1−32

doi: 10.1016/j.survophthal.2008.10.001
[14]

Browning DJ, Stewart MW, Lee C. 2018. Diabetic macular edema: evidence-based management. Indian Journal of Ophthalmology 66:1736−1750

doi: 10.4103/ijo.IJO_1240_18
[15]

Nozaki M, Ando R, Kimura T, Kato F, Yasukawa T. 2023. The role of laser photocoagulation in treating diabetic macular edema in the era of intravitreal drug administration: a descriptive review. Medicina 59:1319

doi: 10.3390/medicina59071319
[16]

Chen Z, Chen B, Hu P, Liu H, Zheng D. 2022. A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema. Advances in Ophthalmology Practice and Research 2:100051

doi: 10.1016/j.aopr.2022.100051
[17]

Kim MW, Moon H, Yang SJ, Joe SG. 2016. Effect of posterior subtenon triamcinolone acetonide injection on diabetic macular edema refractory to intravitreal bevacizumab injection. Korean Journal of Ophthalmology 30:25−31

doi: 10.3341/kjo.2016.30.1.25
[18]

Kishore K, Bhat PV, Venkatesh P, Canizela CC. 2022. Dexamethasone intravitreal implant for the treatment of macular edema and uveitis: a comprehensive narrative review. Clinical Ophthalmology 16:1019−1045

doi: 10.2147/OPTH.S209395
[19]

Mansour SE, Browning DJ, Wong K, Flynn HW Jr, Bhavsar AR. 2020. The evolving treatment of diabetic retinopathy. Clinical Ophthalmology 14:653−678

doi: 10.2147/OPTH.S236637
[20]

Amoaku WM, Ghanchi F, Bailey C, Banerjee S, Banerjee S, et al. 2020. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye 34:1−51

doi: 10.1038/s41433-020-0961-6
[21]

Lin HC, Yang CM, Chen SN, Hsieh YT. 2020. Vitrectomy with internal limiting membrane peeling versus nonsurgical treatment for diabetic macular edema with massive hard exudates. PLoS One 15:e0236867

doi: 10.1371/journal.pone.0236867
[22]

Wu RH, Xu MN, Lin K, Ren MX, Wen H, et al. 2022. Inner limiting membrane peeling prevents secondary epiretinal membrane after vitrectomy for proliferative diabetic retinopathy. International Journal of Ophthalmology 15:1496−1501

doi: 10.18240/ijo.2022.09.13
[23]

Roberts MF, Fishman GA, Roberts DK, Heckenlively JR, Weleber RG, et al. 2002. Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia. British Journal of Ophthalmology 86:658−662

doi: 10.1136/bjo.86.6.658
[24]

Hoerauf H, Brüggemann A, Muecke M, Lüke J, Müller M, et al. 2011. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial. Graefe’s Archive for Clinical and Experimental Ophthalmology 249:997−1008

doi: 10.1007/s00417-010-1610-8
[25]

Xiao K, Dong YC, Xiao XG, Liang SZ, Wang J, et al. 2019. Effect of pars plana vitrectomy with or without cataract surgery in patients with diabetes: a systematic review and meta-analysis. Diabetes Therapy 10:1859−1868

doi: 10.1007/s13300-019-0672-9
[26]

Schreur V, Brouwers J, Van Huet RAC, Smeets S, Phan M, et al. 2021. Long-term outcomes of vitrectomy for proliferative diabetic retinopathy. Acta Ophthalmologica 99:83−89

doi: 10.1111/aos.14482
[27]

Pei M, Zhao X, Wan G. 2023. A systematic review and meta-analysis of clinical outcomes of small gauge vitrectomy with or without intravitreal anti-vascular endothelial growth factor agents pretreatment for proliferative diabetic retinopathy. Ophthalmic Research 66:777−790

doi: 10.1159/000530231
[28]

Yang X, Xu J, Wang R, Mei Y, Lei H, et al. 2016. A randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy. Journal of Ophthalmology 2016:2473234

doi: 10.1155/2016/2473234
[29]

Rush RB, Del Valle Penella A, Reinauer RM, Rush SW, Bastar PG. 2021. Internal limiting membrane peeling during vitrectomy for diabetic vitreous hemorrhage: a randomized clinical trial. Retina 41:1118−1126

doi: 10.1097/IAE.0000000000002976
[30]

Kaneko H, Matsuura T, Takayama K, Ito Y, Iwase T, et al. 2017. Increased retinal thinning after combination of internal limiting membrane peeling and silicone oil endotamponade in proliferative diabetic retinopathy. Ophthalmologica 238:226−235

doi: 10.1159/000479482
[31]

Kumagai K, Ogino N, Furukawa M, Hangai M, Kazama S, et al. 2012. Retinal thickness after vitrectomy and internal limiting membrane peeling for macular hole and epiretinal membrane. Clinical Ophthalmology 6:679−688

doi: 10.2147/opth.s30288
[32]

Ho TC, Yang CM, Huang JS, Yang CH, Yeh PT, et al. 2014. Long-term outcome of foveolar internal limiting membrane nonpeeling for myopic traction maculopathy. Retina 34:1833−1840

doi: 10.1097/IAE.0000000000000149
[33]

Belkin A, Harel G, Shtayer C, Bercovich O, Rubowitz A. 2024. The effect of internal limiting membrane peeling on the inner retinal layers in patients without macular pathologic condition. Retina 44:831−836

doi: 10.1097/IAE.0000000000004042
[34]

Sakamoto M, Hashimoto R, Yoshida I, Ubuka M, Maeno T. 2018. Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. Clinical Ophthalmology 12:2323−2329

doi: 10.2147/OPTH.S184959
[35]

Hasegawa Y, Okamoto F, Sugiura Y, Okamoto Y, Hiraoka T, et al. 2014. Intraocular pressure elevation after vitrectomy for various vitreoretinal disorders. European Journal of Ophthalmology 24:235−241

doi: 10.5301/ejo.5000350
[36]

Yau GL, Silva PS, Arrigg PG, Sun JK. 2018. Postoperative complications of pars plana vitrectomy for diabetic retinal disease. Seminars in Ophthalmology 33:126−133

doi: 10.1080/08820538.2017.1353832
[37]

Rush RB, Gomez PL, Rush SW, Gomez Bastar P. 2023. Internal limiting membrane peeling in patients undergoing vitrectomy for tractional retinal detachment secondary to diabetic retionpathy. Retina 43:1282−1290

doi: 10.1097/IAE.0000000000003812
[38]

Huang CH, Yang CM. 2020. Recurrent retinal detachment after diabetic vitrectomy. International Ophthalmology 40:1931−1939

doi: 10.1007/s10792-020-01366-9
[39]

Wang Q, Zhao J, Xu Q, Han C, Hou B, et al. 2021. Visual outcomes and complications following one-way air-fluid exchange technique for vitreous hemorrhage post vitrectomy in proliferative diabetic retinopathy patients. BMC Ophthalmology 21:129

doi: 10.1186/s12886-021-01885-8
[40]

Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, et al. 2020. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. Jama 324:2383−2395

doi: 10.1001/jama.2020.23027
[41]

Mukai R, Matsumoto H, Akiyama H. 2021. Surgical outcomes of vitrectomy for intractable diabetic macular edema. Graefe’s Archive for Clinical and Experimental Ophthalmology 259:363−368

doi: 10.1007/s00417-020-04898-z
[42]

Matsunaga N, Ozeki H, Hirabayashi Y, Shimada S, Ogura Y. 2005. Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina 25:311−316

doi: 10.1097/00006982-200504000-00010
[43]

Tamura K, Yokoyama T, Ebihara N, Murakami A. 2012. Histopathologic analysis of the internal limiting membrane surgically peeled from eyes with diffuse diabetic macular edema. Japanese Journal of Ophthalmology 56:280−287

doi: 10.1007/s10384-012-0130-y
[44]

Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, et al. 1997. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Investigative Ophthalmology & Visual Science 38:36−47
[45]

Gandorfer A, Rohleder M, Charteris DG, Sethi C, Kampik A, et al. 2005. Staining and peeling of the internal limiting membrane in the cat eye. Current Eye Research 30:977−987

doi: 10.1080/02713680500320745